The Life Sciences team advised RA Pharmaceuticals on its public offering totaling approximately $58 million in gross proceeds from the sale of 9,660,000 shares of common stock at a price of $6.00 per share.
RA Pharmaceuticals will use the net proceeds from the offering to fund its Phase 2 trial for RA101495 for gMG, other pipeline programs, and for working capital and general corporate purposes.
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases.
The Goodwin team was led by partner Robert Puopolo and Alexander Varond.
For more information on the offering, please read the press release.